Neurotrope, Inc. (NTRP) financial statements (2020 and earlier)

Company profile

Business Address 1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1729162611815
Cash and cash equivalents1729162611815
Prepaid expense010010 
Other undisclosed current assets    0 0
Total current assets:1829162613815
Noncurrent Assets
Property, plant and equipment000000 
Total noncurrent assets:000000 
TOTAL ASSETS:1829162613815
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:0322110
Accounts payable031201 
Accrued liabilities000000 
Other undisclosed accounts payable and accrued liabilities      0
Debt    0  
Due to related parties  000  
Other undisclosed current liabilities     00
Total current liabilities:0322110
Noncurrent Liabilities
Total liabilities:0322110
Stockholders' equity
Stockholders' equity attributable to parent, including:17271524(0)(12)(5)
Common stock0000000
Additional paid in capital10610078742874
Accumulated deficit(89)(74)(63)(50)(28)(18) 
Other undisclosed stockholders' equity attributable to parent      (9)
Total stockholders' equity:17271524(0)(12)(5)
Other undisclosed liabilities and equity    121920
TOTAL LIABILITIES AND EQUITY:1829162613815

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit: (0)  (2)  
Operating expenses(16)(11)(13)(13)(9)(9)(8)
Operating loss:(16)(11)(13)(13)(11)(9)(8)
Nonoperating income (expense)
(gain on Contract Termination)
  0    
Other undisclosed income from continuing operations before equity method investments, income taxes0000200
Net loss attributable to parent:(15)(11)(13)(13)(9)(9)(8)
Preferred stock dividends and other adjustments    (0)(2) 
Net loss available to common stockholders, diluted:(15)(11)(13)(13)(10)(11)(8)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(15)(11)(13)(13)(9)(9)(8)
Comprehensive loss, net of tax, attributable to parent:(15)(11)(13)(13)(9)(9)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: